Free Trial

ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics logo with Medical background

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) was the target of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 9,210,000 shares, a growth of 9.1% from the May 15th total of 8,440,000 shares. Based on an average daily trading volume, of 2,780,000 shares, the days-to-cover ratio is presently 3.3 days.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA traded down $0.19 during trading on Monday, hitting $10.44. 2,522,587 shares of the company's stock were exchanged, compared to its average volume of 2,759,805. The firm has a 50-day moving average price of $8.17 and a two-hundred day moving average price of $6.23. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. ADMA Biologics has a 1-year low of $3.06 and a 1-year high of $10.85.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. The firm had revenue of $81.90 million during the quarter, compared to analysts' expectations of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business's revenue for the quarter was up 43.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.03) earnings per share. As a group, analysts expect that ADMA Biologics will post 0.35 earnings per share for the current fiscal year.


Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,081,475 shares of the company's stock, valued at approximately $22,313,412. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. EntryPoint Capital LLC bought a new position in ADMA Biologics in the first quarter valued at approximately $31,000. Simplicity Wealth LLC bought a new position in ADMA Biologics in the first quarter valued at approximately $68,000. Sawgrass Asset Management LLC bought a new position in ADMA Biologics in the third quarter valued at approximately $55,000. Viewpoint Capital Management LLC lifted its stake in ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company's stock valued at $102,000 after buying an additional 2,416 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new position in ADMA Biologics in the third quarter valued at approximately $58,000. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

ADMA has been the subject of a number of analyst reports. HC Wainwright raised their price objective on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a "buy" rating in a report on Friday, May 10th. Mizuho lifted their price target on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, May 10th. Raymond James lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a "strong-buy" rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an "overweight" rating in a research report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $10.50.

View Our Latest Stock Report on ADMA

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

See Also

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines